Early access
Sign in
Not yet taking people in United StatesNo phase

Improving Cervical Cancer Screening for Women Living With HIV in Georgia and Maryland

Studies barriers to cervical cancer screening in women with HIV at clinics.

Key facts

Who runs it
UNC Lineberger Comprehensive Cancer Center
Where
Atlanta and Baltimore, United StatesSee the 2 sites
Trial code
Registry title
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
Status
Not yet recruiting
People taking part
3,500 people, planned
Started
10 Nov 2026
Expected to end
31 Mar 2028
Type of study
Observational, 2 groups
Treatments tested
  • Qualitative interviews
  • Focus groups
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with HIV who get care at certain US clinics, and for clinic staff who care for them. It studies how to improve cervical cancer screening.

Age
Women with HIV: ages 25 to 49 for Aim 1b; ages 25 and over for the chart review (Aim 1a). No age limit is stated for clinic staff.
Sex
Women with HIV take part as patients. Clinic staff of any sex can join.
Biomarker or test result
Living with HIV (for the patient groups).

Main reasons for not taking part

  • Women without an intact cervix (Aim 1b)
  • People who do not work for the Center for Infectious Diseases at the University of Maryland School of Medicine in Baltimore, MD or the Ponce de Leon Clinic at Emory University in Atlanta, GA (Aim 2)

The registry criteria, word for word

Show all 8 criteriaShow less

Other criteria

  • Aim 1a- Retrospective Chart Review Inclusion Criteria: Health records of WWH who are ages 25 and over, clients of the participating clinics, and eligible for cervical cancer screening per national US guidelines, during the time period of September 1, 2022 to August 31, 2025
  • Aim 1b Inclusion Criteria
  • women with Human Immunodeficiency Virus (HIV) receive care
  • ages between 25- 49
  • eligible for cervical cancer screening per national US guidelines; Aim 1b Exclusion Criteria • Women without an intact cervix; Aim 2 Inclusion Criteria:
  • Clinical team members who work and provide care to women living with HIV at three clinical locations: the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD; Ponce de Leon Clinic at Emory University in Atlanta, GA; and Albany Area Primary Health Care in Albany, GA
  • Clinical team members will include: providers (Physicians, Nurse practitioners, Physician's Assistants, Nurses, Nursing Assistants, Medical Assistants, Pharmacists), laboratory members, or other staff involved in clinic operations; Aim 2 Exclusion Criteria
  • Individuals who do not work for the Center for Infectious Diseases (CID) at the University of Maryland School of Medicine in Baltimore, MD or the Ponce de Leon Clinic at Emory University in Atlanta, GA

Where in United States

  • Emory University SOM Division/Department: Gynecology & ObstetricsAtlanta, United StatesContact: Lisa Flowers, MD, MPHNot yet recruiting
  • University of Maryland School of Medicine Division of Family and Community MedicineBaltimore, United StatesContact: Gregory Taylor, MDNot yet recruiting

About the trial

What the trial wants to find out

The purpose of the CASCADE-3002 project is to improve access to cervical cancer screening among women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites. This study will assess the cervical cancer screening cascade and identify multilevel factors that impede access to screening among women with HIV attending Infectious Disease clinics in Georgia and Maryland. In parallel, the study will explore and develop implementation strategies for human papillomavirus (HPV) self-collection to increase screening uptake, adherence, and appropriate clinical follow-up in this population at elevated risk for cervical cancer.

Read full original descriptionShow less

Cervical cancer remains a preventable malignancy; however, women with HIV are at substantially increased risk and experience higher rates of cervical cancer compared with women without HIV. The World Health Organization has called for the global elimination of cervical cancer as a public health problem, defined as fewer than 4 incident cases per 100,000 women annually, with targets for vaccination, screening, and treatment coverage. Although the United States has the tools to approach near-elimination, disparities in healthcare access and screening persist, particularly among women with HIV.

The 2 groups in the trial

  • Women with Human Immunodeficiency Virus (HIV)

    Women with Human Immunodeficiency Virus (HIV) are eligible for cervical cancer screening.

    Treatment: Qualitative interviews

  • Healthcare providers

    Healthcare providers (e.g. physicians, nurse practitioners, physician's assistants, nurses, nursing assistants, medical assistants, pharmacists), laboratory members, and IT Specialist/Medical Records Experts providing care to WWH.

    Treatment: Focus groups

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
Plain-language title
Improving Cervical Cancer Screening for Women Living With HIV in Georgia and MarylandGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 October 2026